BofA analyst Jason Gerberry lowered the firm’s price target on Amphastar (AMPH) to $31 from $32 and keeps a Neutral rating on the shares. Based on Q3 pricing and volume trends for key drugs as well as relevant company commentary, the firm previewed Q3 EPS updates for its commercial-stage biopharma coverage, telling investors that it does not expect any major Q3 beats/misses and no big 2026 revisions among the group.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMPH:
- Amphastar Signs $2.8M Research Agreement with Hanxin
- Amphastar price target raised to $32 from $28 at BofA
- Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights
- Amphastar Pharmaceuticals: Strategic Positioning and Robust Pipeline Justify Buy Rating
- Amphastar announced FDA approval of iron sucrose injection